Company profile for Tyra Biosciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Tyra Biosciences is targeting new pathways of acquired resistance in oncology with purpose-built drugs for the benefit of patients. Acquired resistance is a devastating reality for patients initially responding to targeted cancer therapies. As new therapies have become more selective, resistance has become a major limitation. The need from patients and the demand from the market to address this problem has never been stronger....
Tyra Biosciences is targeting new pathways of acquired resistance in oncology with purpose-built drugs for the benefit of patients. Acquired resistance is a devastating reality for patients initially responding to targeted cancer therapies. As new therapies have become more selective, resistance has become a major limitation. The need from patients and the demand from the market to address this problem has never been stronger. Tyra has built a nimble and experienced team to rapidly translate new discoveries into the clinic with a singular focus on acquired resistance in oncology.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
2333 State St. Suite 201, Carlsbad, CA 92008
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/tyra-biosciences-announces-participation-at-upcoming-investor-events-302613236.html

PR NEWSWIRE
13 Nov 2025

https://www.prnewswire.com/news-releases/tyra-biosciences-reports-third-quarter-2025-financial-results-and-highlights-302606089.html

PR NEWSWIRE
05 Nov 2025

https://www.prnewswire.com/news-releases/tyra-biosciences-announces-first-child-dosed-in-beach301-its-phase-2-study-for-dabogratinib-tyra-300-in-pediatric-achondroplasia-302535255.html

PR NEWSWIRE
21 Aug 2025

https://www.prnewswire.com/news-releases/tyra-biosciences-announces-participation-at-upcoming-investor-events-302534890.html

PR NEWSWIRE
20 Aug 2025

https://www.prnewswire.com/news-releases/tyra-biosciences-reports-second-quarter-2025-financial-results-and-highlights-302530524.html

PR NEWSWIRE
14 Aug 2025

https://www.prnewswire.com/news-releases/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025-302500095.html

PR NEWSWIRE
09 Jul 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty